VIM
BMRN icon

VELA Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

VELA Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,584
Closed -$484K – 137
2023
Q2 		$484K Buy
5,584
+1,042
+23% +$98.1K 0.22% 113
2023
Q1 		$442K Buy
4,542
+1,050
+30% +$109K 0.2% 117
2022
Q4 		$361K Hold
3,492
– – 0.18% 122
2022
Q3 		$296K Buy
+3,492
New +$311K 0.17% 124

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VELA Investment Management's BMRN Position: Q3 2023 in Review

VELA Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 5,584 shares — an estimated $484K sold.

VELA Investment Management first reported a position in BMRN in Q3 2022 and held it in 4 quarters. The position peaked at $484K in Q2 2023. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

  • VELA Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • VELA Investment Management sold 5,584 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $484K.
  • VELA Investment Management first reported a position in BioMarin Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • VELA Investment Management's BioMarin Pharmaceuticals position peaked at $484K in Q2 2023.
  • 519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on VELA Investment Management's 13F filing for Q3 2023, filed 7 Nov 2023.